PRPHOTCPharmaceutical PreparationsFiscal year ends December 31
ProPhase Labs, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026
$0.01−0.00 (-6.16%)
Close on Oct 19, 2026
- Market cap
- $119.68K
- P/E (TTM)
- –
- Dividend yield
- –
ProPhase Labs, Inc. revenue by segment
By business segment
| Revenue | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | TTM Q1 23 | TTM Q4 22 | TTM Q3 22 | TTM Q2 22 | TTM Q1 22 | TTM Q4 21 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Consumer products | – | $15.48M | $18.39M | $10.14M | $21.14M | $18.93M | $16.48M | $14.32M | $13.23M | $11.90M | $10.57M | $10.48M | – | – |
| Diagnostic Services [Member] | – | $2.49M | $10.33M | $24.85M | $41.57M | $59.62M | $77.94M | $108.33M | $132.76M | $119.36M | $100.74M | $68.56M | – | – |
By product or service
By region
From the segment and revenue-disaggregation notes of ProPhase Labs's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.